This morning, Compass Pathways shared its Q3 2026 results, which included an update on its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA) submission. “Final NDA submission nearing completion”, the first bullet point in the release states, “and will be filed in the next two weeks.” “With the imminent completion of our NDA submission and the potential for a…
